<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02074189</url>
  </required_header>
  <id_info>
    <org_study_id>2012XLC02-1</org_study_id>
    <secondary_id>2012XLC02</secondary_id>
    <nct_id>NCT02074189</nct_id>
  </id_info>
  <brief_title>Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer</brief_title>
  <official_title>Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southwest Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effect of adjuvant chemotherapy to control tumor progression in patients after cystectomy for
      locally advanced bladder cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Effect of adjuvant chemotherapy based on Gemcitabine and Cisplatin to control tumor
      progression in patients after cystectomy for locally advanced bladder cancer.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cancer progressive free survival rate</measure>
    <time_frame>60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Adjuvant Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adjuvant Chemotherapy(Gemcitabine, Cisplatin):Gemcitabine 1000 mg/m2 iv,D1,D8,D15;cisplatin 70 mg/m2 iv,D2.With 4 cycles. Treatment begins between 1-5 weeks after radical operation (within 42 days is recommended)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No immediate post-surgery treatment. Patients undergo observation followed by cisplatin and gemcitabine as in arm I at local relapse, or receive intravenously chemotherapy with cisplatin and gemcitabine at multiple metastases</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine, Cisplatin</intervention_name>
    <description>Gemcitabine 1000 mg/m2 iv,D1,D8,D15;cisplatin 70 mg/m2 iv,D2.With 4 cycles. Treatment begins between 1-5 weeks after radical operation (within 42 days is recommended)</description>
    <arm_group_label>Adjuvant Chemotherapy</arm_group_label>
    <other_name>GCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 18 years of age or older, estimated life expectancy ≥ 6 months.

          2. Pathologically confirmed localized invasive bladder cancer following standardize
             radical cystectomy and pelvic lymphadenectomy.

          3. Transitional cell carcinoma of bladder, stage pT3N0M0.Transitional cell carcinoma may
             be with or without squamous cell carcinoma and/or adenocarcinoma components.

          4. Electrocorticography(ECOG) performance status 0-2.

          5. Blood routine:Absolute neutrophil count (ANC) ≥ 1500/μL,White blood cell count ≥
             3000/μLPlatelets ≥ 100,000/μL,Hemoglobin ≥ 10.0 g/dL,

          6. Total serum bilirubin≤ 1.5 x upper limit of normal (ULN).Serum aspartate transaminase
             (AST; serum glutamic oxaloacetic transaminase(SGOT)) and serum alanine transaminase
             (ALT; serum glutamic pyruvic transaminase (SGPT)) ≤ 2.5 x upper limit of normal (ULN).

          7. Creatinine clearance rate,Ccr ≥ 60%

          8. ECG：no arrhythmias, no myocardial infarction.

               -  Signed and dated informed consent document indicating that the patient (or
                  legally acceptable representative) has been informed of all pertinent aspects of
                  the trial prior to enrollment.

               -  Willingness and ability to comply with scheduled visits, treatment plans,
                  laboratory tests,and other study procedures.

        Exclusion Criteria:

          1. Past history of systemic chemotherapy

          2. Serious heart and lung dysfunction.

          3. Associated with central or peripheral neuropathy greater than 2 grade.

          4. Evidence of distant metastasis beyond the pelvis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiwen Chen, M.D,Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southwest Hospital, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southwest hospital,China</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2014</study_first_submitted>
  <study_first_submitted_qc>February 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2014</study_first_posted>
  <last_update_submitted>February 27, 2014</last_update_submitted>
  <last_update_submitted_qc>February 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southwest Hospital, China</investigator_affiliation>
    <investigator_full_name>Zhiwen Chen</investigator_full_name>
    <investigator_title>M.D,Ph.D</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

